Demand is growing for mammalian cell banking in support of the monoclonal antibody therapeutic and cell and gene therapy fields.  Proper cell line development followed by GMP banking is required in order to introduce your therapeutic product candidate into clinical trials.  In addition to protein/viral production levels and molecule structural attributes, regulatory considerations are needed during final clone selection prior to transitioning to GMP banking.

During this webinar, our experts will focus on mammalian cell line development and GMP banking requirements to transition your research from an R&D environment to the GMP regulated manufacturing world to take your molecule into the clinic.  Some of the topics that will be discussed during this webinar include:

• Cell line development considerations for CHO and HEK-293/Sf9
• Cell line selection and clonality
• GMP documentation and GMP cell bank production
• Considerations for characterization and release testing of production cells banks for clinical use

Presenters:

	Stanley Prince Senior Scientific Advisor, Biologics Eurofins BioPharma Product Testing
As a Senior Scientific Advisor for Eurofins BioPharma Product Testing, Mr. Prince provides technical and commercial support for GMP Biosafety services for large molecule and cell and gene therapy projects, helping clients to navigate specialized testing needs. Mr. Prince has worked for large molecule and cell and gene therapy CRO’s his entire career, bringing over 17 years of experience to his role at Eurofins. He earned a B.S. degree in life sciences from Penn State University and an M.B.A. from Alvernia University.
	Francisca Neethling, Ph.D. Head of Biotherapeutic Services Eurofins Discovery
Francisca Neethling, Ph.D. is the Head of Eurofins Discovery Biotherapeutic Services. She brings over 25 years of academic, start-up and pharmaceutical Industry experience to support portfolio and program strategy for large molecule drug discovery. Dr. Neethling holds a B.Sc. in Microbiology and Genetics and an M.Sc. and Ph.D. in Transplantation Immunology. She was a Postdoctoral Fellow at the Transplantation Biology Research Center at Harvard Medical School and at Oklahoma State University. Prior to joining Eurofins Discovery in 2021, Dr. Neethling spent almost 10 years as a Sr. Principal Scientist in the antibody discovery group at Boehringer Ingelheim, developing novel biologics across a range of therapeutic areas.